Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity

Slides:

Advertisements

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Shin-Ichi Nishikawa, MD, PhD

Serum cytotoxic T lymphocyte–associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy Daniele Saverino, BS, Anna.

Allergic Rhinitis and Its Impact on Asthma

Ulf Darsow, MD, Dieter Vieluf, MD, Johannes Ring, MD, PhD

Damage of the pharyngeal mucosa and hyperresponsiveness of airway in sinusitis Giovanni Rolla, MDa, Paola Colagrande, MDa, Ermanno Scappaticci, MDb, Flavia.

The effect of omalizumab on nasal allergic inflammation

Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation Alvin M. Sanico, MDa, Satsuki Atsuta, MDa,

Youngil I. Koh, MD a, Inseon S

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD

Practice Notes from the AAAI

Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the.

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Noninjection routes for immunotherapy

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Elephantiasis nostras: A case report

Jerome A. Sigua, MD, Becky Buelow, MD, Dorothy S

The impact of allergic rhinitis on bronchial asthma

Conjunctivitis medicamentosa

Cellular and mediator responses twenty-four hours after local endobronchial allergen challenge of asthmatic airways Anthony J. Frew, MD, Johanne St-Pierre,

Erythema multiforme to phenobarbital: Involvement of eosinophils and T cells expressing the skin homing receptor F.Jesus Gonzalez, PhDa, Maria J. Carvajal,

Jesús Merayo-Lloves, MD, Tong Z. Zhao, MD, James E. Dutt, BA, C

Nobuhisa Terada, MDa, Akiyoshi Konno, MDb, Kiyoshi Togawa, MDa

Practice Notes from the AAAAI

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model John M.

A review of the current guidelines for allergic rhinitis and asthma

Early decreases in blood eosinophil levels with reslizumab

Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge Adriaan.

Pathophysiology of the inflammatory response

News & Notes Journal of Allergy and Clinical Immunology

Allergens in school dust: II

Basophils and eosinophils in allergic rhinitis

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma Mamert Milewski, MD, Lucyna Mastalerz, MD, Ewa Niżankowska, MD, Andrzej.

Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and.

Costimulatory molecules in the developing human gastrointestinal tract: A pathway for fetal allergen priming Catherine A. Jones, PhD, Gillian H.S. Vance,

Patterns of pollen cross-allergenicity

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Autophagy: Nobel Prize 2016 and allergy and asthma research

News & Notes Journal of Allergy and Clinical Immunology

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study Giovanni B. Pajno,

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Fractional analysis of sequential induced sputum samples during sputum induction: Evidence that different lung compartments are sampled at different time.

Loratadine reduces allergen-induced mucosal output of α2-macroglobulin and tryptase in allergic rhinitis Lennart Greiff, MD, PhDa, Carl G.A. Persson,

Ligation of IgE receptors causes an anaphylactic response and neutrophil infiltration but does not induce eosinophilic inflammation in mice Masayuki.

Seasonal rhinitis and azelastine: Long- or short-term treatment

Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: The British perspective Helen Donohoe, MSc (Econ)

Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma Lena Håkansson,

Practice Notes from the AAAI

Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis Toyoyuki Hanazawa, MD, PhD, Julio.

Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen Catherine.

Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway.

Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro.

Alvaro A. Cruz, MD, Robert M

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Nasal challenge with allergen leads to maxillary sinus inflammation

Footnotes1 Journal of Allergy and Clinical Immunology

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Follicular thyroid cells of autoimmune thyroiditis may coexpress ICAM-1 (CD54) and its natural ligand LFA-1 (CD11a/CD18) Marcello Bagnasco, MDa, Giampaola.

Tuomas Jartti, MD, James E. Gern, MD

Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4,

News & Notes Journal of Allergy and Clinical Immunology

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal.

Advances in mechanisms of allergic disease in 2016

Presentation transcript:

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity Giorgio Ciprandi, MD, Caterina Pronzato, MD, Giovanni Passalacqua, MD, Vittorio Ricca, MD, Jan Grögen, G.S. Mela, Paolo Varese, MD, Claudia Bertolini, MD, Marcello Bagnasco, MD, Giorgio Walter Canonica, MD Journal of Allergy and Clinical Immunology Volume 98, Issue 6, Pages 1088-1096 (December 1996) DOI: 10.1016/S0091-6749(96)80196-5 Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 1 Patients’ total symptom scores after specific allergen nasal challenge, evaluated at T0 and T7. Median values are represented by thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 1 Patients’ total symptom scores after specific allergen nasal challenge, evaluated at T0 and T7. Median values are represented by thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 2 Neutrophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 3 Eosinophil counts at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 4 ICAM-l/CD54 expression on nasal epithelial cells (evaluated by alkaline phosphatase–antialkaline phosphatase and expressed as positivity score, see text) at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions

FIG. 5 ECP levels in nasal lavages at T0 and T7, before challenge (PRE-CHALL.) and after challenge (EPR and LPR). Median values are shown as horizontal thick bars. Journal of Allergy and Clinical Immunology 1996 98, 1088-1096DOI: (10.1016/S0091-6749(96)80196-5) Copyright © 1996 Mosby, Inc. Terms and Conditions